Skip to content
Screener

Jade Biosciences JBIO Enterprise value

Enterprise value at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$120.2B+7.2%
Climb Global Solutions, Inc. logo
Climb Global Solutions, Inc.CLMB
$325.15M-32.2%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$2.68B+65.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$2.83B+85.0%
Vor Biopharma logo
Vor BiopharmaVOR
$704.51M+902%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K—
Free cash flow-$33.7M—

Valuation

See full
Market cap$1.35B+436%

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity0×—
Current ratio14.3×-17.7×

Where this comes from

Calculated from Jade Biosciences’s reported figures.

$692.9Mmarket cap+$808.0Ktotal debt−$55.1Mcash and equivalents=$638.62M

The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:27 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212088

FAQ

What is Jade Biosciences's enterprise value?
Jade Biosciences (JBIO) reported enterprise value of $638.62M in Q1 2026.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about Jade Biosciences's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude